Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,624.70
(
-1.36%
)
US TECH 100
23,776.40
(
-1.48%
)
Dow Jones
46,225.15
(
-1.63%
)
Brent Oil
107.10
(
6.41%
)
Bitcoin
71,324.92
(
-3.54%
)
News Focus
News Focus
Post# of 257257
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122795
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: mcbio post# 79070

Wednesday, 07/20/2011 11:16:39 PM

Wednesday, July 20, 2011 11:16:39 PM

Post# of 257257
IDRA—Here we go again with TLR-targeted drugs…

http://finance.yahoo.com/news/Idera-Reports-Clinical-Hold-bw-3688989363.html?x=0&.v=1

…a proposed Phase 2 protocol that the Company had recently submitted under an Investigational New Drug Application for IMO-3100 will be placed on a clinical hold. The proposed Phase 2 trial of IMO-3100 is for the treatment of psoriasis… IMO-3100, an antagonist of TLR7 and TLR9, is a lead clinical candidate in development to treat autoimmune and inflammatory diseases.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now